Emma Conroy, PA
Medical · Hamburg, NYNPI 1538846472
Payments from drug & device makers
Across 127 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$257
- Amgen$229
- Lilly USA, LLC$225
- BETA Bionics, Inc.$217
- Tandem Diabetes Care, Inc.$191
- AbbVie$175
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $257 |
| Amgen | 15 | $229 |
| Lilly USA, LLC | 16 | $225 |
| BETA Bionics, Inc. | 15 | $217 |
| Tandem Diabetes Care, Inc. | 4 | $191 |
| AbbVie | 9 | $175 |
| Medtronic | 3 | $166 |
| Sequel Med Tech, LLC | 4 | $126 |
| TG Therapeutics, Inc. | 1 | $125 |
| Boehringer Ingelheim | 7 | $119 |
| Insulet Corporation | 4 | $109 |
| Bayer | 3 | $69 |
| Recordati_rare_diseases_inc. | 3 | $67 |
| IBSA Pharma Inc. | 3 | $59 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| Radius Health, Inc. | 2 | $52 |
| Mannkind Corporation | 2 | $49 |
| Dexcom, Inc. | 3 | $45 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $32 |
| Abbott | 1 | $27 |
| Almatica Pharma LLC | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $15 |
| Cequr Corporation | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,501 in reported general payments places this provider in the 80th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 276 | $404,153 |
| OzempicSemaglutide | 254 | $384,711 |
| JardianceEmpagliflozin | 155 | $217,747 |
| TrulicityDulaglutide | 57 | $91,725 |
| RybelsusSemaglutide | 41 | $86,942 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $37,948 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $35,417 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $35,109 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $23,891 |
| FarxigaDapagliflozin Propanediol | 14 | $23,045 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $21,219 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $14,756 |
| SynthroidLevothyroxine Sodium | 131 | $13,384 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $11,563 |
| HumalogInsulin Lispro | 20 | $6,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $225 | $502,007353 claims |
| Novo NordiskOzempic, Rybelsus | $257 | $471,654295 claims |
| Boehringer IngelheimJardiance | $119 | $217,747155 claims |
| AbbVieSynthroid | $175 | $13,384131 claims |
| IBSA Pharma Inc.Tirosint | $59 | $4,36413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $2,659170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,395 medical providers in New York.
Other medical in Hamburg
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.